Selank

Tuftsin-related heptapeptide · neurobiology research reagent

≥ 99.0% · target, verify batch COACAS 129954-34-3RUO

Research statusPreclinical and limited human literature

Supplied formLinear heptapeptide

Lead time10–18 days

Selank — White to off-white lyophilized powder

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research themes include GABA-related gene expression, enkephalin-degrading enzymes, BDNF signalling, stress-related behaviour and immunology
Evidence strength varies by endpoint and is predominantly preclinical; these themes are not clinical benefit claims.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 129954-34-3
Formula: C₃₃H₅₇N₁₁O₉
Molecular weight: About 751.9 Da
Appearance: White to off-white lyophilized powder
Purity: ≥ 99.0% · target, verify batch COA
Storage: Store and ship according to the batch-specific COA, SDS and stability statement for the supplied form. Do not transfer storage conditions from a finished product or another salt form; request solution-stability data for the intended matrix before preparing working solutions.
MOQ: On request
Lead time: 10–18 days

PubChem CID 11765600

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Selank

Selank is the synthetic linear heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), structurally related to the tuftsin sequence and extended with a Pro-Gly-Pro motif. Peer-reviewed literature includes biochemical and animal work plus a PubMed-indexed Russian randomized comparative study of 62 patients with generalized anxiety disorder or neurasthenia. That study compared Selank with medazepam and reported similar anxiolytic effects, but it was small, used an active comparator rather than a placebo, was published in Russian and has not been independently replicated in a geographically diverse program. The independently verifiable human evidence base therefore remains limited. Historical or foreign-market drug use does not establish approval or clinical equivalence for this RUO material.

Research topics reported in the literature include anxiety-related behaviour, neurotransmission, memory, BDNF signalling and immune pathways
Human evidence is limited and does not establish a broadly accepted clinical indication for this RUO reagent.

Mechanism context

The question the literature is testing

Mechanistic studies report that Selank altered neurotransmission-related gene expression in rat frontal cortex, with partial overlap and time-dependent correlation with GABA treatment. Separate biochemical work reported inhibition of enkephalin degradation, and animal studies reported BDNF-related changes. These results support several hypotheses rather than one established receptor-level mechanism; most evidence is preclinical and should not be extrapolated to efficacy or safety in humans.

Evidence map

Research routes and exposure context

Evidence tierMixed evidence context

Research areaNeurocognitive research

Routes reported in sources

Intranasal

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Public literature does not provide a comprehensive, independently replicated long-term human safety dataset
This material is for qualified laboratory research only and is not a finished drug, sterile preparation or product for human or veterinary administration.

Interactions reported in the literature

No controlled interaction dataset supports combination recommendations for this RUO material
Any multi-analyte or co-exposure study requires its own compatibility, assay-interference and safety assessment.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Selank factory batch COAs

Selank 5 mg Factory batch COA protected preview

Selank5 mg · WHJLP-SK5-260710-B

Selank 10 mg Factory batch COA protected preview

Selank10 mg · WHJLP-SK10-260710-B

Selank 11 mg Factory batch COA protected preview

Selank11 mg · WHJLP-SK11-260710-B

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Request any additional sequence, content, solvent or counterion evidence only when the buyer's written procedure requires it and the scope has been agreed
HPLC area purity alone does not establish identity, content, sterility, endotoxin status or stability.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

SELK-05MG5 mg10 vials

SELK-10MG10 mg10 vials

SELK-11MG11 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Store and ship according to the batch-specific COA, SDS and stability statement for the supplied form. Do not transfer storage conditions from a finished product or another salt form; request solution-stability data for the intended matrix before preparing working solutions.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Volkova A, Shadrina M, Kolomin T, et al. Front Pharmacol. 2016;7:31. PMCID PMC4757669, PMID 26924987. In rat frontal cortex, the study assessed 84 neurotransmission-related genes after Selank or GABA exposure; 7 low-expression genes were excluded, 77 were analyzed, 45 changed at 1 hour and 22 at 3 hours. The overall expression-change patterns correlated positively at 1 hour (r = 0.86, p ≤ 0.05) and negatively at 3 hours (r = -0.39, p ≤ 0.05), supporting a GABAergic modulation hypothesis rather than proving a single receptor mechanism.
Zozulya AA, Kost NV, Sokolov OYu, et al. Bull Exp Biol Med. 2001;131(4):315-317. PMID 11550013, DOI 10.1023/a:1017979514274. Selank dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin in the reported assay (IC50 15 μM); this supports an enkephalinase-related biochemical hypothesis but does not establish clinical efficacy for a supplied RUO lot.
Zozulya AA, Neznamov GG, Siuniakov TS, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID 18454096. This Russian-language randomized comparative study included 62 patients (Selank n=30; medazepam n=32) with generalized anxiety disorder or neurasthenia and reported similar anxiolytic effects on the stated scales. Its small active-comparator design, limited accessible reporting and lack of broad independent replication constrain generalization and do not establish approval, equivalence or suitability of this RUO material.
The FDA document Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026, does not list Selank in Category 1, 2 or 3. FDA previously recorded removal of Selank acetate (TP-7) from Category 2 after receiving information that the nominator intended to nominate a different substance. Removal from a nomination category is not inclusion on the 503A Bulks List, drug approval or authorization for a specific compounded product.

01
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2008 · peer-reviewed original research (randomized comparative clinical trial)
Open source
02
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity
Bulletin of Experimental Biology and Medicine · 2001 · peer-reviewed original research
Open source
03
Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank
Regulatory Peptides · 2011 · peer-reviewed original research
Open source
04
Antiviral activity of immunomodulator Selank in experimental influenza infection
Voprosy Virusologii (Problems of Virology) · 2009 · peer-reviewed original research
Open source
05
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Frontiers in Pharmacology · 2016 · peer-reviewed original research
Open source
06
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats
Bulletin of Experimental Biology and Medicine · 2019 · peer-reviewed original research
Open source
07
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Behavioural Neurology · 2017 · peer-reviewed original research
Open source
08
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
U.S. Food and Drug Administration · 2026 · official U.S. regulatory process record
Open source

Product FAQ

Questions buyers ask about Selank

What identity should a Selank lot document?+

The free-peptide reference is the linear sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), CAS 129954-34-3, PubChem CID 11765600, formula C₃₃H₅₇N₁₁O₉ and average molecular weight about 751.9 Da. A salt, counterion or terminal modification is a different supplied form and should be identified separately on the label and batch COA.

What does the published evidence establish for Selank?+

Peer-reviewed studies report GABA-related gene-expression changes, inhibition of enkephalin-degrading enzymes and BDNF-related effects, mainly in animal or in-vitro models; a limited Russian clinical literature also exists. These findings support research hypotheses, but they do not establish benzodiazepine equivalence, a definitive receptor mechanism or clinical suitability of an independently supplied RUO lot.

What should a buyer review before qualifying a Selank lot?+

Confirm the exact sequence and terminal state, supplied form and counterion, intact-mass result, chromatographic method and purity result, peptide-content or assay basis, water and residual-solvent information, and the released-lot storage statement. Request endotoxin, bioburden, sterility or solution-stability data only when the intended laboratory workflow requires them; do not infer these attributes from HPLC area purity alone.

Selank

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Selank

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Selank factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia

The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity

Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank

Antiviral activity of immunomodulator Selank in experimental influenza infection

Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats

Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A

Questions buyers ask about Selank

Compare adjacent molecules and documentation needs.

Semax

DSIP

P21 (P021)

PE-22-28